TLR2 and COVID-19: For example, the U.S. FDA has approved an investigation into the efficacy of a PUL-042 inhalation solution that blocks TLR2/6/9 to reduce the infection rate, progression, and disease severity of COVID-19 (NCT04312997, NCT04313023) [42,86].